WuXi Biologics expands manufacturing to Singapore with $60m facility

By Flora Southey

- Last updated on GMT

WuXi Biologics is expanding its manufacturing site network to Singapore with the construction of a $60m facility for clinical and small volume commercial production.

The contract development and manufacturing organisation (CDMO) will invest S$80m ($60m) in the facility and hire 150 employees for WuXi Biologics​’ first Asian site outside of China.

The Singapore facility will house 4,500L bioreactor capacity with two 2,000L traditional fed-batch and one 500L perfusion-based continuous processing for both clinical and small volume commercial production.

The CDMO will also install bioprocessing capabilities for early-stage development.

The investment will “initiate our first overseas Asian site in Singapore and enable local companies and expedite biologics development in Asia,” ​said CEO Chris Chen in a statement.

WuXi already has a client base in Singapore, including Zika virus antibody developer Tychan, a spokesperson told us earlier today.

Singapore’s Economic Development Board - which is supporting the development – said the investment will introduce WuXi’s bioprocessing technology platform to the region.

“Its presence here will also strengthen our ecosystem for supporting biotech companies from Singapore and beyond,” ​said chairman Beh Swan Gin in a statement.

The Singapore site marks WuXi Biologics’ third manufacturing facility announcement this year.

Earlier this month, we reported​ the CDMO’s plans to build a biomanufacturing facility in Ireland with single-use bioreactors and continuous bioprocessing capabilities for commercial production.

And last week​, WuXi Biologics’ said it would build a biologics centre in Northern China to offer both commercial and clinical manufacturing services.

Related topics Bio Developments

Related news

Show more

Follow us